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Controlled release evaluation 
of paracetamol loaded amine 
functionalized mesoporous silica 
KCC1 compared to microcrystalline 
cellulose based tablets
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Saeed Shirazian2,3,7,8 & Gavin M. Walker2
In the pharmaceutical manufacturing, drug release behavior development is remained as one of the 
main challenges to improve the drug effectiveness. Recently, more focus has been done on using 
mesoporous silica materials as drug carriers for prolonged and superior control of drug release in 
human body. In this study, release behavior of paracetamol is developed using drug-loaded KCC-1-NH2 
mesoporous silica, based on direct compaction method for preparation of tablets. The purpose of this 
study is to investigate the utilizing of pure KCC-1 mesoporous silica (KCC-1) and amino functionalized 
KCC-1 (KCC-1-NH2) as drug carriers in oral solid dosage formulations compared to common excipient, 
microcrystalline cellulose (MCC), to improve the control of drug release rate by manipulating surface 
chemistry of the carrier. Different formulations of KCC-1 and KCC-NH2 are designed to investigate 
the effect of functionalized mesoporous silica as carrier on drug controlled-release rate. The results 
displayed the remarkable effect of KCC-1-NH2 on drug controlled-release in comparison with the 
formulation containing pure KCC-1 and formulation including MCC as reference materials. The pure 
KCC-1 and KCC-1-NH2 are characterized using different evaluation methods such as FTIR, SEM, TEM 
and  N2 adsorption analysis.
Recently, mesoporous silica materials as drug  carrier1–3 have been widely used for improving the release rate 
of poorly water soluble drugs and delivering of therapeutic  proteins4 due to their intrinsic  properties5 such as 
non-toxic nature, good biocompatibility, easy functionalization, wide surface area with tunable pore size, high 
capacity of drug  loading6–13, and superior capability to immobilize therapeutic  molecules14. The majority of new 
drugs illustrate very poor bioavailability and  solubility15–17, which lead to very low release rate during dissolution 
 tests18–23. So far, in order to overcome this obstacle as one of the biggest challenges in pharmaceutical industry, 
different research groups have focused on displaying the potential of surface-functionalized mesoporous silica 
 materials24–26 as an important host for oral drug controlled delivery  systems27–32. Different researches have been 
done on enhancement and control of drug release rate and  solubility33 by loading drug into mesoporous silica 
 materials19,34–37.
Various studies have been carried out on drug administration methods and the influence of that on drug 
delivery  systems38 in the human  body39–43. Drug delivery systems play a key role to improve drug effectiveness 
and safety through controlling the drug release rate, release time and place in human  body44. It is essential to 
develop a drug delivery system for all therapeutics to improve their influence on  patients45. Paracetamol is a 
type of nonsteroidal anti-inflammatory  drug46, that is used commonly as pain relief treatment. Paracetamol 
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absorption is very fast in the small intestine which can cause severe side effects such as liver  damage47,48. Then, it 
is essential to develop a controlled-release system for  paracetamol49 especially in situation of overdose to over-
come the problem of fatal liver  damage50. Furthermore, the therapeutic behavior of paracetamol is improved by 
developing an engineered release system for  that51–53.
Lim et al. investigated the release kinetics of ibuprofen and paracetamol utilizing fluorescent MSNs as drug 
 carrier12. They found out that the release rate of paracetamol was higher than ibuprofen due to higher solubility 
of paracetamol. They also investigated the kinetics of drug release rate, and illustrated that ibuprofen release rate 
is dependent on solution pH, while higher release rate was obtained at lower pH. On the other hand, for the case 
of paracetamol, their results did not show significant difference at different pH and it was influenced by interac-
tion between materials and  molecules12. In another study, Szegedi et al. synthesized and amine-functionalized 
silica MCM-41 and SBA-15 using post-synthesise method. They studied the adsorption and release behaviour 
of ibuprofen from functionalized and drug loaded mesoporous silica. Their results revealed the possibility of 
ibuprofen controlled release rate by amine-functionalization of mesoporous  silica54. AbouAitah et al. studied 
the release behaviour of Quercetin using amine-functionalized silica MCM-41 and KCC-1 as drug carrier. Their 
results illustrated that the synthesized MCM-41 and KCC-1 materials can be used as efficient drug controlled 
release host for long-term release in drug delivery  systems55.
A series of mesoporous silica nanoparticles (MSNs) were used by Zhang et al. to develop and improve the sol-
ubility and release rate of poorly water drugs by increasing the capacity of drug loading on MSNs applying acetic 
acid as loading solvent via soaking  method56. Their findings revealed that the capacity of drug loading is strongly 
associated to the pore size and pore volume of MSNs. Moreover, in another research, Qu et al. investigated the 
controlled release of Captopril utilizing mesoporous silica nanoparticles via different types of  surfactants57. They 
explained that the pore size and morphology of mesoporous silica showed significant effect on drug release 
behavior and be able to control the release rate. Horcajada and co-authors tested MCM-41 mesoporous silica to 
study the effect of pore size of materials on drug delivery  behavior58, which showed, reduction in the material 
pore size, results in a reduction in the drug delivery rate. Mellaerts et al. evaluated the bioavailability of poorly 
soluble drug (itraconazole) using drug loaded ordered mesoporous silica (OMS)59. They studied the in vivo and 
in vitro drug release rate from OMS and then compared with the release of pure crystalline drug. Their results 
showed that, OMS drug loaded displays faster drug release rate than pure itraconazole. Additionally, they com-
pared the drug release rate from OMS with the sporanox as marketed drug and found that OMS can be applied 
as a promising drug carrier to improve the bioavailability of poorly water soluble  drugs59.
Heikkila et al. loaded ibuprofen into mesoporous TUD-1 using soaking method to study the drug delivery 
 system60. Their results indicated successful inclusion of ibuprofen with very high efficiency as model drug into 
the TUD-1 followed by significant potential of mesoporous silica materials to increase the drug release rate with 
96% release after 2 h via dissolution  test60. Ayad et al. utilized amine-functionalized mesoporous silica KIT-6 as 
a drug delivery carrier to study the controlled release behavior of  drug61. They investigated the release behavior 
of drug at two different pH, gastric fluid (pH 2) and intestinal fluid (pH 7.4). They illustrated the significant 
influence of KIT-6-NH2 as mesoporous silica for drug loading to enhance drug release rate due to the interaction 
of hydrogen bonds of functional groups in the drug molecules, such as carboxyl and carbonyl  groups61. Kinnari 
et al. studied and compared the effect of mesoporous silica and non-ordered mesoporous silica as drug carriers 
on the drug release  behavior27.
Follmann et al. studied the sustained delivery of antitumor drug, camptothecin, which is poorly-water solu-
ble drug using functionalized nanoporous silica KCC-1 with methyl groups. Then, functionalized KCC-1 was 
mixed with poly vinyl alcohol (PVA) and poly acrylic acid (PAA) to make hybrid aerogels to improve the drug 
delivery  system62.
Mesoporous silica KCC-163,64 with privilege morphology such as fibrous surface, numerous surface area and 
dendrimeric structure and in addition, superior mechanical stability can be considered as one of the unprecedent 
types of mesoporous silica in drug delivery systems as drug  carrier65.
Herein, first, we illustrated the synthesis of mesoporous  silica66 KCC-1 which possesses high surface area due 
to existence of  dendrimeric67 fibrous structure and their respective channels, which make it as an attractive host 
for drug  delivery68–76. It should be pointed out that, according to the literature, the fibrous morphology of KCC-1 
silica is unprecedented, thereby it is considered as a high-performance carrier for therapeutic molecules. KCC-1 
demonstrated supreme physical properties such as high surface area, fibrous morphology, and great thermal/
hydrothermal as well as mechanical stability. The singularity of KCC-1 is related to its high surface area owing to 
fibrous nature of KCC-1 instead of pores, which causes to be easily  available77. Then, we presented the utilization 
of KCC-1-NH2 as drug carrier to improve the drug release behavior during the in vitro dissolution tests. The 
functionalized KCC-1 and the pure KCC-1 were characterized using different characterization techniques such 
as scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform infrared 
spectroscopy (FTIR), and Nitrogen adsorption/desorption.  Paracetamol78 was used as model drug in this project.
Materials
Cetyltrimethylammonium bromide (CTAB) (Merck KGaA, Germany) was purchased from Merck. 3-amino-
propyl triethoxysilane (APTS), Tetraethylorthosilicate (TEOS, 98%), toluene anhydrous, 1-pentanol, urea and 
cyclohexane were purchased from Sigma-Aldrich. Paracetamol (4-acetamidophenol, Phion) was used as model 
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Methods
Synthesis of mesoporous silica KCC-1. Purely dendritic fibrous siliceous KCC-1 was synthesized 
according to a method by Polshettiwar and co-workers68. In brief, first a suspension of 1 g CTAB and 0.6 g of urea 
in 30 ml deionized water was prepared. Afterward, the suspension was stirred for 2 h at room temperature. Then, 
the second suspension was prepared using 30 ml of cyclohexane, 1.5 ml of 1-pentanol and 2.5 g of tetraethyl 
orthosilicate (TEOS). The first prepared suspension was added to the mixture under stirring. The stirring of the 
final suspension continued for further 2 h. Then, the mixture was transferred to a Teflon-sealed hydrothermal 
reactor and, then placed in oven for 5 h at 120 °C. As next step, the suspension was centrifuged in 6500 rpm for 
3 min. Then, the solid product was washed twice with acetone and deionized water. The final materials dried in 
oven for 24 h at 60 °C. Finally, the white powder was furnace-calcined at 550 °C for 5 h in order to remove CTAB 
template (calcination process).
Functionalization of mesoporous silica KCC-1 using aminopropyl triethoxysilane (APTES). For 
functionalization of the KCC-1 with n-propyl amine groups (Pr-NH2) to obtain KCC-1-NH2, post grafting 
method was  used79. For achieving this goal, 1 g of KCC-1 was added to 50 ml of dry toluene and ultrasonicated 
for 15 min. Then, 1 ml of APTES was added to the mixture and magnetically stirred under reflux at 110 °C for 
12 h. After cooling down to room temperature, the mixture was filtered and washed several times with toluene 
and ethanol and oven-dried at 60 °C for 24 h. The white powder of KCC-1-NH2 was then successfully obtained.
Drug loading procedure. For paracetamol loading into the KCC-1 and KCC-1-NH2, solvent evaporation 
method was employed. 150 mg of KCC-1 and 150 mg of paracetamol were mixed, and 1 ml of ethanol was added 
to the mixture. As the next step, the mixture was ultrasonicated for 10 min and dried in the room temperature 
for 48 h19. This procedure was repeated for drug loading on KCC-1-NH2 as well.
Tableting procedure. A single-punch tablet press (Gamlen Tableting GTD-1 D series) was used to com-
pact the 100 mg drug loaded KCC-1 and KCC-1-NH2 to tablet shape, in 6 mm die by direct compaction method. 
400 kg was considered as tablet loading, and the compaction rate was set at 180 mm/min80,81.
Dissolution test procedure. In vitro dissolution test was done utilizing a pharma PTWS 120D 6-station 
tablet dissolution testing instrument (Hainburg, Germany). Phosphate buffer was used as dissolution medium 
at 37 ± 0.5  °C80,82,83. In order to study the release characteristics of paracetamol from the parent mesoporous 
silica KCC-1 and KCC-1-NH284,85, in vitro release experiments were done by keeping constant the stirring rate 
at 50 rpm and temperature at 37 ± 0.5 °CC for paracetamol according to the  USP64. Dissolution tests were done 
with 900 ml of buffer solution as medium during 4 h for phosphate buffer solution (PBS) at pH 7 and gastric 
buffer solution at pH of 1.2. During the dissolution test, 5 ml of each sample was withdrawn every 10 min until 
60 min, then every 1 h. The buffer was replaced immediately with the same amount to keep the total volume 
constant at 900 ml. At the end, all samples were diluted using the same buffer and analyzed utilizing UV at 
wavelength of 249 nm.
Scanning electron microscopy and transmission electron microscopy. For analysing the mor-
phology and particle size of KCC-1 and KCC-1-NH2 samples, field-emission electron microscope (FE-SEM, 
Hitachi SU8030, Japan) was carried out. The surface morphology of KCC-1 and KCC-1-NH2 were characterized 
utilizing high-resolution transmission electron microscopy (HRTEM, JEOL JEM-2011F electron microscope). 
Sample preparation was done by drop-casting a suspension of sample in ethanol on TEM Cu grids followed by 
drying in air.
Fourier transform infrared spectroscopy. Fourier transform infrared (FTIR) spectroscopy was per-
formed for the functionalized and non-functionalized KCC-1 samples. Nicolet Nexus FTIR spectrometer 
between 400 and 4000 cm−1 was utilised and equipped with an attenuated total reflectance accessory (ATR).
N2 adsorption–desorption isotherms. To study the Brunauer–Emmet–Teller equation (BET) specific 
surface area of KCC-1 and KCC-1-NH2 samples, the multipoint method was applied. For measuring the pore 
size distribution of the samples, Barrett–Joyner–Halenda (BJH) method on a Quantachrome Autosorb-1 instru-
ments, using the desorption branches of the isotherms was considered. The samples were vacuum degassed at 
120 °C overnight before starting the analysis.
Results and discussion
SEM and TEM analysis. For analyzing the particle size, structural and morphological features of KCC-1 
and KCC-1-NH2, SEM and TEM analyses were carried out. From SEM images in Fig. 1, it is observed that both 
particles have spherical morphology, which are made by nano-sized dendrimeric fibers. The SEM observations 
of samples show that the morphology and size do not change during functionalization process by  NH2 groups. 
Also, according to the particle size distribution histogram of KCC-1, the mean particle size diameter of KCC-1 
prepared in this work is about 0.74 μm. Also, no considerable changes were observed in KCC-1 shape and par-
ticle size distribution after functionalization using amine  groups86.
To investigate the structure of KCC-1 and KCC-1-NH2, TEM analysis was performed. In Fig. 2, the TEM 
images reveal that both pure KCC-1 and KCC-1-NH2 possess monodispersed fibrous silica spheres where the 
dendrimeric fibers uniformly grow—along with the free radial directions—from the center of the spheres. Also, 
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after surface functionalization, there was no noticeable change in the fibrous and spherical structure of the KCC-
1, and the structure remains intact. It is reported that the existence of nanoporous silica fibers in the structure 
of KCC-1 efficiently renders molecular accessibility to the surface of KCC-1 in comparison to other types of 
mesoporous silica materials which makes KCC-1 as an attractive candidate for drug delivery and controlled 
release  applications49,87,88.
FT-IR analysis. Figure 3 illustrates the FT infrared spectra of the KCC-1 (curve a) and the KCC-1-NH2 
(curve b) recorded in the region 4000–400 cm−1. For both samples, the absorption peaks at 1091 cm–1, 800 cm–1, 
and 464 cm–1 were assigned to asymmetric, symmetrical stretching and bending vibration of Si–O–Si bond, 
respectively. The spectral band at 1627 cm–1 in samples is due to the –OH deformation band of water molecules 
remained in the matrix. For the KCC-1-NH2 sample, the band at 1471  cm–1 in the spectrum indicated the 
existence of the N–H bending vibration of the –NH2 groups. Two bands at 2932 cm–1 and 2856 cm–1 are cor-
responded to the νCH of the –CH2 groups of propyl chain, indicating the successful formation of amine groups 
after modification.
N2 adsorption–desorption isotherms. N2 adsorption–desorption analysis was performed for study of 
the porous structural feature of the samples. Figure 4 shows the results of obtained  N2 adsorption–desorption 
isotherms for KCC-1 and KCC-1-NH2 at 77 K and P/P0 = 0.99. Both curves have type- IV isotherm based on the 
IUPAC classification, which is usual for mesosphere  silica55. As it is clear in the Fig. 4 and Table 1, the KCC-1 
sample illustrated wider pore size distribution in comparison with KCC-1-NH2. In addition, KCC-1 shows 
higher specific surface area compared to the KCC-1-NH2. Pore size distribution of samples using non-local den-
sity functional theory (NLDFT) model are also shown in Fig. 4. The average pore diameter of KCC-1 and KCC-
1-NH2, according to the BJH method, is 2.4 and 2.2 nm, respectively. There is a reduction in the specific surface 
area and pore size distribution. All these changes can prove a successful functionalization process. These—a 
reduction in surface area, pore size and pore volume- are typical phenomena observed during functionalization 
of mesoporous silica materials via post-modification or post-grafting  method89.
Figure 1.  FESEM images of (a) KCC-1 and (b) KCC-1-NH2. The middle diagram is particle size distribution 
for KCC-1.
Figure 2.  TEM images of (a) KCC-1 and (b) KCC-1-NH2 particles.
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Thermogravimetric analysis (TGA). Thermal stability of the KCC-1 and KCC-1-NH2 was studied by 
TGA  analysis90 under a nitrogen atmosphere. As indicated in Fig. 5, a weight-loss below 120 °C was seen for the 
samples due to the loss of organic solvent and/or physiosorbed  water91—which were used during the preparation 
of KCC-1 and KCC-1-NH2—from the surface of the samples. The weight loss of KCC-1 between 120 and 800 °C 
was mostly because of the thermal decomposition of silanol hydroxyl groups (Si–OH) and residual organic 
moiety (CTAB). Under the same condition, the weight of grafted APTES on the fibers of KCC-1 determined 
from the TGA was about 8.8%. For KCC-1-NH2, the weight loss between 400 and 800 °C is mainly because of 
Figure 3.  FTIR spectra of (a) KCC-1 and (b) KCC-1-NH2 samples.
Figure 4.  Nitrogen adsorption–desorption of KCC-1 and KCC-1-NH2 and pore size distribution (inset) of 
samples utilizing non-local density functional theory (NLDFT) model.
Table 1.  Textural properties of mesoporous silica KCC-1 and KCC-1-NH2 according to the BET and BJH 
models. SBET specific surface area according to the BET method, Vtot. total pore volume, D BJH average pore 
diameter.
Samples SBET  (m2 g−1) Vtot.  (cm3 g−1) D (nm)
KCC-1 356 0.49 2.4
KCC-1-NH2 248 0.40 2.2
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the decomposition of the organic residue [i.e., organic part (amino propyl) of the covalently attached APTES], 
beside the above-mentioned weight loss for pure KCC-1. TGA results proved that a large amount of the APTES 
molecules (8.8%) have been chemically attached onto the surface of silica fibers of KCC-1 and these samples are 
stable up to 450 °C (> 30% weight loss) in a nitrogen flow atmosphere.
X-ray diffraction. To understand the crystalline structure of the KCC-1, KCC-1-NH2, and KCC-1-NH2-
Pra, low-angle X-ray diffraction (L-XRD) patterns of all materials were recorded on a PANalytical Empyrean 
diffractometer, operated at 40 kV and 40 mA using Cu Kα radiation (λ = 0.154 nm). The patterns of the samples 
are shown in Fig. 6. This silica materials demonstrated only a broad diffraction peak at 2θ = 1°–2.5°, indicat-
ing the low ordering of the silica framework in samples. This kind of broad diffraction peak at low angle has 
already been interpreted in terms of disordered pore structure and wormhole-motif structure in previous stud-
ies—where functionalized materials were prepared by post-grafting  method57–61. The peak intensity for pure 
mesoporous KCC-1 was somewhat decreased upon surface functionalization with APTES, indicating that the 
introduction of silane coupling agent affected the pore structure. After drug loading in KCC-1-NH2 (KCC-1-
NH2-Para sample) the peak intensity was decreased slightly again, which was predictable.
In vitro dissolution tests of drug loaded KCC-1 and KCC-1-NH2. Three different formulations are 
considered to investigate the effect of KCC-1 and KCC-1-NH2 on paracetamol release rate. The first formulation 
was considered as reference and contains MCC as a common excipient in oral solid dosage formulation and par-
acetamol as drug, 1:1 (w/w). The second formulation includes drug loaded KCC-1 as drug carrier, 1:1 (w/w). In 
addition, in the third formulation, drug loaded KCC-1-NH2 is utilized as drug carrier, 1:1 (w/w). The formula-
Figure 5.  TGA curves of KCC-1 and KCC-1-NH2 under  N2 atmosphere from 25 to 800 °C at a heating rate of 
10 °C/min−1.
Figure 6.  Low angle-XRD patterns of the samples.
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tion containing MCC was considered to compare the drug release rate from the common oral solid formulation 
and mesoporous silica-based drug loaded of oral solid dosage formulation.
The release profiles of those three formulations are plotted in Figs. 7 and 8. As presented in the graphs, the 
concentration of released paracetamol at both pH, 1.2 and 7, is a function of time and monitored using UV 
analysis. The graphs also illustrate the ability of mesoporous silica KCC-1 and KCC-1-NH2 to use as drug carrier 
for regulating the drug release rate compared to MCC as a common excipient in oral solid dosage formulations. 
In addition, the results show the reduction of drug release rate for KCC-1-NH2 and its ability to use as drug 
carrier for prolonged and controlled release of drug. Figures 7 and 8 reveal the cumulative percent of released 
paracetamol from MCC-Para (paracetamol), KCC-1-Para and KCC-1-NH2-Para tablets at pH 7 for 240 min. 
The graphs show that the release rate of paracetamol from KCC-1-NH2-Para tablet is slower than KCC-1-Para 
tablet. In addition, in Fig. 8, it is clear that the paracetamol release equilibrium rates are higher for the KCC-1-
Para tablet compared to the KCC-1-NH2-Para tablet at pH 1.2. The release rate can be dependent on the stronger 
and weaker interactions between amine-functional groups of KCC-1-NH2 and functional groups in paracetamol 
including amide (–CO–NH2) and hydroxyl (–OH) groups,  respectively23,54,92. These interactions result in slower 
Figure 7.  Release rate of paracetamol from MCC-Para, KCC-1-Para and KCC-1-NH2-Para tablets at pH 7.
Figure 8.  Release rate of paracetamol from MCC-Para, KCC-1-Para and KCC-1-NH2-Para tablet at pH 1.2.
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release rate for the KCC-1-NH2-Para. The release graphs presented that functionalized KCC-1 was able to adjust 
the drug release rate due to the existence of the –NH2 groups by reducing the invasion of PBS in the pores and 
leads to a lag in drug  release23. Moreover, steric hindrance of amine groups leads to inhibiting the drug release 
from silica KCC-155,64. Another reason for reduction of drug release rate could be due to narrower pore size of 
silica KCC-1-NH2 after amine  functionalization54,55.
Moreover, the structure of mesoporous silica KCC-1 such as wide surface area, pores, fibrous and dendrimeric 
structure leads to enhance the drug loading capacity and improve the transmission rate of drug molecule by 
controlling the release  rate66. However, the drug release from the mesoporous silica was controlled by diffusion 
mechanism through their pores. Therewith, drug release rate is dependent on the chemical structure of model 
drug and interaction between the paracetamol, functional decoration of mesoporous silica and phosphate buffer 
solution. Furthermore, the drug release is influenced by the existence of hydrophilic groups in the paracetamol 
structure such as hydroxyl, carboxyl and amide  groups13,23. The drug release can be also related to the pore 
diameter of mesopore silica. Effect of pH on the release rate of paracetamol is not significant, but under pH 1.2, 
the release rate is slightly higher which could be due to protonation of hydroxyl groups in KCC-1 and amine 
groups in KCC-1-NH248,64. Higher solubility of paracetamol in phosphate buffer could be due to the existence 
of hydroxyl, carboxyl and amide groups which are known as hydrophilic  groups12,92–95.
Conclusions
In this work, mesoporous silica KCC-1 was synthesized by sol–gel-hydrothermal method and functionalized 
by amino-groups using post grafting method to prepare KCC-1-NH2 for controlled release applications. Both 
synthesized and functionalized KCC-1 were characterized utilizing SEM, TEM, FTIR and  N2 adsorption analysis 
in terms of pore size, surface area, morphology, structure and functional groups. Afterwards, release character-
istics of drug loaded KCC-1 and KCC-1-NH2 were studied at different pH, 7 and 1.2. As the results presented, 
the produced mesoporous silica as drug carrier was suitable for drug loading due to its outstanding properties. 
The drug release rate was remarkably impressed by intermolecular interaction between paracetamol and KCC-
1-NH2, and between paracetamol and phosphate buffer solution as well. Based on these findings, mesoporous 
KCC-1-NH2 can be considered as a promising carrier for drug delivery systems to control the drug release rate, 
specifically for highly soluble drugs, such as paracetamol.
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